Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35-55, in multiple sclerosis patients

被引:9
|
作者
Cossu, Davide [1 ]
Mameli, Giuseppe [1 ]
Masala, Speranza [1 ]
Cocco, Eleonora [2 ]
Frau, Jessica [2 ]
Marrosu, Maria Giovanna [2 ]
Sechi, Leonardo Antonio [1 ]
机构
[1] Univ Sassari, Dept Biomed Sci, Sect Expt & Clin Microbiol, I-97100 Sassari, Italy
[2] Univ Cagliari, Dept Publ Hlth Clin & Mol Med, Multiple Sclerosis Ctr, I-09124 Cagliari, Italy
关键词
Myelin oligodendrocyte glycoprotein; Multiple sclerosis; Bacillus Calmette-Guerin; Mycobacterium avium subspecies; paratuberculosis; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AVIUM-SUBSPECIES-PARATUBERCULOSIS; BACILLE CALMETTE-GUERIN; CENTRAL-NERVOUS-SYSTEM; SARDINIAN PATIENTS; ANTIBODIES; INFECTION; PATHOGENESIS; EPITOPES; CELLS;
D O I
10.1016/j.jns.2014.09.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Bacillus Calmette-Guerin (BCG) and Mycobacterium avium subspecies paratuberculosis (MAP) have been associated with multiple sclerosis (MS). Clinical data indicates that BCG vaccination exerts anti-inflammatory effects in MS; conversely, MAP is thought to be one of the possible infectious factors responsible of MS through a molecular mimicry mechanism. A peptide-based indirect ELISA was used to detect antibodies against the encephalitogenic myelin oligodendrocyte glycoprotein (MOG)(35-55) epitope, and two mycobacterial peptides sharing sequence homology with the latter: MAP_2619c(352-361)/BCG_1224(355-364) and BCG_3329c(64-74). Among 40 MS patients and 39 healthy volunteers included in the study, only MOG(35-55) was capable of inducing a significantly higher humoral response in MS subjects compared to controls. Indeed, 11 out of 40 MS subjects (27.5%) and only 2 out of 39 controls (5%) were antibody-positive for MOG(35-55) (p = 0.01, AUC = 0.65). These findings strengthen the importance of MOG(35-55) in MS pathogenesis. The MAP and BCG MOG-homologues epitopes investigated were not recognized in MS patients. Overall, the results allow us concluding that sharing homology of linear epitopes is necessary but not sufficient to induce antibody-mediated cross-reactivity. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:78 / 81
页数:4
相关论文
共 50 条
  • [41] Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
    Petrone, Linda
    Tortorella, Carla
    Aiello, Alessandra
    Farroni, Chiara
    Ruggieri, Serena
    Castilletti, Concetta
    Meschi, Silvia
    Cuzzi, Gilda
    Vanini, Valentina
    Palmieri, Fabrizio
    Prosperini, Luca
    Haggiag, Shalom
    Galgani, Simona
    Grifoni, Alba
    Sette, Alessandro
    Gasperini, Claudio
    Nicastri, Emanuele
    Goletti, Delia
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [42] Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients
    Torgauten, Hilde M.
    Onyango, Therese Bredholt
    Ljostveit, Sonja
    Hallin, Erik I.
    Serkland, Trond T.
    Skrede, Silje
    Langeland, Nina
    Cox, Rebecca Jane
    Wergeland, Stig
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [43] Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab
    Bar-Or, Amit
    Aburashed, Rany
    Chinea, Angel R.
    Hendin, Barry A.
    Lucassen, Elisabeth
    Meng, Xiangyi
    Stankiewicz, James
    Tullman, Mark J.
    Cross, Anne H.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [44] Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab
    Hendin, B. A.
    Cross, A. H.
    Chinea, A. R.
    Tullman, M. J.
    Aburashed, R.
    Stankiewicz, J.
    Lucassen, E.
    Meng, X.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 367 - 367
  • [45] Humoral response to SARS-CoV-2 natural Infection and mRNA vaccines among patients with multiple sclerosis
    Jaber, A.
    Greco, C.
    Sylvester, A.
    Tremblay, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 574 - 574
  • [46] Humoral immune response to SARS-CoV-2 booster vaccination in patients with multiple sclerosis and healthy controls
    Krajnc, N.
    Riedl, K.
    Hegen, H.
    Traxler, G.
    Leutmezer, F.
    Di Pauli, F.
    Kornek, B.
    Rommer, P.
    Zulehner, G.
    Duerauer, S.
    Bauer, A.
    Kratzwald, S.
    Winklehner, M.
    Deisenhammer, F.
    Guger, M.
    Hoeftberger, R.
    Berger, T.
    Bsteh, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 793 - 793
  • [47] Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy
    Rod, Brit Ellen
    Wergeland, Stig
    Bjornevik, Kjetil
    Holmoy, Trygve
    Ulvestad, Elling
    Njolstad, Gro
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [48] Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy
    Rod, Brit Ellen
    Wergeland, Stig
    Bjornevik, Kjetil
    Holmoy, Trygve
    Ulvestad, Elling
    Njolstad, Gro
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 363 - 364
  • [49] Influence of disease modifying treatments on humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients
    Zecca, C.
    Disanto, G.
    Sacco, R.
    Bernasconi, E.
    Gobbi, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 84 - 84
  • [50] The prognostic value of intrathecal immune response against axonal components in patients with multiple sclerosis
    Seidi, OA
    Semera, YK
    Gregson, NA
    Sharief, MK
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (01): : 141 - 141